Correlation Between Zentalis Pharmaceuticals and Travere Therapeutics

Can any of the company-specific risk be diversified away by investing in both Zentalis Pharmaceuticals and Travere Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Zentalis Pharmaceuticals and Travere Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Zentalis Pharmaceuticals Llc and Travere Therapeutics, you can compare the effects of market volatilities on Zentalis Pharmaceuticals and Travere Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Zentalis Pharmaceuticals with a short position of Travere Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Zentalis Pharmaceuticals and Travere Therapeutics.

Diversification Opportunities for Zentalis Pharmaceuticals and Travere Therapeutics

-0.15

Correlation Coefficient

Zentalis Pharmaceuticals  Travere Therapeutics

Good diversification

The 3 months correlation between Zentalis and Travere is -0.15. Overlapping area represents the amount of risk that can be diversified away by holding Zentalis Pharmaceuticals Llc and Travere Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Travere Therapeutics and Zentalis Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Zentalis Pharmaceuticals Llc are associated (or correlated) with Travere Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Travere Therapeutics has no effect on the direction of Zentalis Pharmaceuticals i.e., Zentalis Pharmaceuticals and Travere Therapeutics go up and down completely randomly.

Pair Corralation between Zentalis Pharmaceuticals and Travere Therapeutics

Given the investment horizon of 90 days Zentalis Pharmaceuticals Llc is expected to under-perform the Travere Therapeutics. In addition to that, Zentalis Pharmaceuticals is 1.56 times more volatile than Travere Therapeutics. It trades about -0.01 of its total potential returns per unit of risk. Travere Therapeutics is currently generating about 0.11 per unit of volatility. If you would invest  1,427  in Travere Therapeutics on September 14, 2024 and sell it today you would earn a total of  364.00  from holding Travere Therapeutics or generate 25.51% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Zentalis Pharmaceuticals Llc  vs.  Travere Therapeutics

Zentalis Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Zentalis Pharmaceuticals Llc has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent basic indicators, Zentalis Pharmaceuticals is not utilizing all of its potentials. The current stock price mess, may contribute to short-term losses for the institutional investors.

Travere Therapeutics

Risk-Adjusted Performance

8 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Travere Therapeutics are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady basic indicators, Travere Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Zentalis Pharmaceuticals and Travere Therapeutics

The main advantage of trading using opposite Zentalis Pharmaceuticals and Travere Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Zentalis Pharmaceuticals position performs unexpectedly, Travere Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Travere Therapeutics will offset losses from the drop in Travere Therapeutics' long position.

The idea behind Zentalis Pharmaceuticals Llc and Travere Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.